月度归档： 2025 年 6 月

KUALA LUMPUR, MALAYSIA, June 25, 2025 - (ACN Newswire via SeaPRwire.com) - The 3rd edition of the ASEAN Procurement Innovation Summit & Awards (APIS25) concluded on a high note, affirming its role as the region’s most influential platform for procurement, supply chain, and sourcing professionals. Over two packed days, more than 250 delegates came together to explore transformative strategies, disruptive technologies, and leadership approaches shaping the next generation of procurement.A Strategic Platform for Innovation and InsightUnder the theme “The Next Frontier in Procurement Excellence: Elevating Standards, Driving Results, Shaping the Future”, APIS25 featured a forward-looking agenda built around five strategic pillars: AI adoption, ESG integration, digital procurement, supply chain resilience, and talent development.The summit hosted high-level keynotes, Oxford-style debates, real-world case studies, fireside chats, and panel discussions—offering attendees deep insights into the evolving role of procurement in driving organizational value and societal impact.Session HighlightsAI in Procurement & Resilient ContractingNorlela Tukiban (Telekom Malaysia) shared how AI-powered contract intelligence is redefining supplier risk, spend agility, and compliance.Oxford Debate: Long-Term Value vs. Cost SavingsModerated by Jan Piskadlo (Ben Line Group) and featuring Luke Kenny, Dr. Sanjay Kumar Gupta, and Alwaleed Alabdulwahed, this lively session dissected the trade-offs between short-term gains and long-term strategic value.Oxford Debate Stage: Is Generative AI Truly Transforming Procurement?An engaging session moderated by Zyad Khan (Dubai World Trade Centre) brought together top thinkers including Rym Khelil (SLB), Carl Kimball (Zycus), Jan Piskadlo (Ben Line Group), and Nisa Camalia (CBRE Asia Pacific) to evaluate the real-world potential of generative AI in procurement.Supply Chain Evolution: Nearshoring & ResilienceA dynamic panel explored regional strategies to navigate disruption, enhance transparency, and foster local sourcing.Digital Procurement TransformationIn partnership with Gold Sponsor Zycus, this session demonstrated how next-gen automation and predictive analytics are revolutionizing sourcing operations.Celebrating Excellence: ASEAN Procurement Awards 2025The highly anticipated ASEAN Procurement Awards recognized organizations and professionals driving impactful change across leadership, ESG, innovation, and transformation.Award Winners:EDOTCO Group – Leaders in Procurement Transformation for Resilient Supply ChainsBIOCON – Visionaries in Sustainable Supply Chain ExcellenceShell Malaysia – Future Leader of the Year & Supply Chain Initiative of the Year (Derrick Lopez)PERKESO – Women in Procurement Award (Fadhilah Binti Hamil)Tahakom – Procurement Innovation Award (Alwaleed Alabdulwahed)Dubai World Trade Centre – Highly Recommended: Leaders in Procurement Transformation for Resilient Supply ChainsAward SpotlightJayaprakash Krishnan, Head of Group SCM Shared Services at EDOTCO Group, delivered a high-impact presentation showcasing how EDOTCO’s strategic transformation elevated procurement from a transactional role to a future-ready value driver.A Heartfelt Thank You to Our Advisory PanelThe success of APIS25 was anchored by the guidance of our respected Advisory Board:Dr. Christina SS Ooi, Luke Kenny, Jonathan Cheung, and Yang Chor Leong. Their behind-the-scenes leadership ensured the integrity, relevance, and rigor of the summit and awards.Voices that Moved the RoomWe thank our inspiring speakers including Tom Bollen, Dr. Christina SS Ooi, Rachael Bah, Jonathan Cheung, and Luke Kenny, whose insights and authenticity elevated conversations and ignited new thinking.Lucky Draw & Community MomentsThe summit closed with an energizing Lucky Draw hosted by Chairperson Tom Bollen, leaving attendees with unforgettable memories and generous giveaways.Thank You to Our Sponsors, Exhibitors & PartnersA heartfelt thank you to the sponsors and partners who helped bring this vision to life:Platinum Sponsor: GEPGold Sponsors: Zycus, iCertis, Bahwan CyberTek, Green TapeSilver Sponsor: SPEEDExhibitors: SAIBA International, Esker, Lapasar, Olive Technologies, JSOFT SolutionYour unwavering commitment to innovation and collaboration was key to APIS25’s impact and reach.To our Supporting Associations and Media Partners, thank you for amplifying our mission, championing innovation, and connecting us to wider communities across the region. Your collaboration helped us reach new heights.Together, we’ve sparked conversations, celebrated excellence, and shaped the future of procurement in ASEAN.Looking ForwardAPIS25 wasn’t just an event, it was a movement toward procurement excellence across ASEAN. As we continue to shape the future of procurement, we remain committed to collaboration, capability-building, and community impact.See you at APIS26!For more information, please contact:Amina KanteSenior Marketing ManagerCT Event AsiaPhone: +601161888699Email: aminak@cteventasia.com Website: https://www.aseanprocurementsummit.com/requestRegistration: www.aseanprocurementsummit.com/request  Copyright 2025 ACN Newswire via SeaPRwire.com.

BUFFALO, NY, June 23, 2025 - (ACN Newswire via SeaPRwire.com) - ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows. As H5N1 outbreaks continue to rise globally, the need for robust quality control materials has never been greater. ZeptoMetrix's Influenza A H5N1 Quantitative Stock offers laboratories a comprehensive quality control material that requires RNA extraction, unlike traditional naked RNA products. This novel solution includes three encapsulated H5N1 gene segments within a phage-like particle, ensuring realistic validation of extraction, amplification, and detection steps."The ongoing H5N1 pandemic highlighted the urgent need for reliable diagnostic tools," said Dr. Karuna Sharma, PhD, Vice President & Chief Scientific Officer of Antylia Diagnostics division. "This launch represents a significant advancement in diagnostic quality control. By encapsulating RNA within a phage-like particle, we enable labs to have confidence in their results at every step. This is not just innovation; it is vital in the fight against H5N1 and other emerging RNA viruses."NATtrol Influenza A H5N1 Quantitative Stock (Product Code: 0831198) is NATtrol inactivated to enhance stability and provided with precision quantification at 1,000,000 gene copies/mL of each gene segment, verified by digital PCR (dPCR). The ready-to-use 1 mL format integrates seamlessly with ZeptoMetrix's -STQ product line, streamlining workflow adoption.More information on how to order and additional ZeptoMetrix products can be found at: www.zeptometrix.comAbout ZeptoMetrix®ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.Product Page: https://www.zeptometrix.com/us/en/nattrol-influenza-a-h5n1-quantitative-stock-1-x-10-ml-15355Contact InformationAndrew ZengerGlobal Product Managerandrew.zenger@antylia.com(716) 715-7417SOURCE: ZeptoMetrixRelated Documents:ZeptoMetrix H5N1 Press Release.pdf Copyright 2025 ACN Newswire via SeaPRwire.com.

- The Executive Centre has further expanded at JP Tower Level 11, following the successful launch of Level 14, showcasing strong demand for premium workspace solutions.- The upcoming GranTokyo South Tower centre, set to open in September 2025, will be TEC's fifth centre in the Tokyo Station/Marunouchi area and twelfth centre in Japan.- TEC reinforces its position as a leading premium flexible workspace provider, poised to meet the needs of high-growth sectors like technology and AI.Japan，Jun 24, 2025 - (ACN Newswire via SeaPRwire.com) - The Executive Centre (“TEC”), the leading premium flexible workspace provider in Asia Pacific and the Middle East, is pleased to announce the opening of its new centre at JP Tower Level 11, which has already achieved an impressive 80% pre-sale occupancy, and further complements the existing Level 14 centre in the same iconic building. This expansion follows the successful launch of Level 14 in April 2024, which brings TEC’s mature Tokyo Station portfolio to 100% occupancy, reflecting the robust demand for TEC’s premium flexible workspaces in this vibrant location.Following this expansion, TEC’s total footprint in JP Tower exceeds 30,000 sq ft. The JP Tower Level 11 centre mirrors the elegance and sophistication of its Level 14 counterpart, featuring a natural-light lounge, private offices which could accommodate from 6 to 100 people, meeting room facilities, and an event space for up to 40 people. The centre also includes enhanced amenities, such as soundproof phone booths, a dedicated private server room, and a stylish pantry area, all designed to elevate the workplace experience.In addition to this exciting expansion, TEC is thrilled to also announce the forthcoming opening of the GranTokyo South Tower centre, scheduled for September 2025. This centre will mark TEC's fifth centre in the Tokyo Station/Marunouchi area as well as its twelfth centre in Japan, offering breathtaking views of Tokyo Station and the Yaesu district. Designed for enterprise clients, particularly in technology and AI sectors, it will feature signature elements of TEC with advanced amenities including height-adjustable digital standing desks, ergonomic Herman Miller chairs and Salto Bluetooth-enabled door locks, ensuring alignment to TEC’s premium offerings.Liam Owens, City Head of Tokyo & Yokohama at The Executive Centre, stated, “The ongoing investment and strategic growth of TEC in the Tokyo Station/Marunouchi area underscores our commitment to delivering exceptional premium flexible workspace solutions. With the launch of JP Tower Level 11 and the upcoming GranTokyo South Tower, TEC is well-positioned to support high-growth sectors and solidifying our leadership position as the premium flexible workspace provider in Japan.”Looking ahead to 2026, TEC plans to further expand with additional centres, ensuring to meet the evolving needs of businesses in Tokyo and beyond. This strategy reflects TEC's unwavering dedication to fostering dynamic work environments with the highest quality in workspace solutions and services, catering to the demands of today’s workforce.About The Executive CentreThe Executive Centre (TEC) is Asia’s premium flexible workspace provider, opened its doors in Hong Kong in 1994 and today boasts over 220+ Centres in 36 cities and 16 markets. It is the third largest serviced office business in Asia.The Executive Centre caters to ambitious professionals and industry leaders looking for more than just an office space - they are looking for a place for their organisation to thrive. TEC has cultivated an environment designed for success with a global network spanning Greater China, Southeast Asia, North Asia, India, Sri Lanka, the Middle East, and Australia, with sights to go further and grow faster. Each Executive Centre offers a prestigious address with the advanced infrastructure to pre-empt, meet, and exceed the needs of its Members. Walking with Members through every milestone and achievement, The Executive Centre empowers ambitious professionals and organisations to succeed.Privately owned and headquartered in Hong Kong, TEC provides first class Private and Shared Workspaces, Business Concierge Services, and Meeting & Events facilities to suit any business' needs.www.executivecentre.comPress EnquiriesThe Executive CentrePebble LeePebble_lee@executivecentre.com / +852 3951 9888 Copyright 2025 ACN Newswire via SeaPRwire.com.

MALANG, E. JAVA, Indonesia, June 24, 2025 - (ACN Newswire via SeaPRwire.com) - A research team from Brawijaya University (UB) has identified two new microalgae genera in the waters around Bawean Island, Gresik Regency, East Java, and Tomini Bay, Central Sulawesi.Lecturer of the Faculty of Fisheries and Marine Sciences (FPIK) Oktiyas Muzaky Luthfi, S.T., M.Sc. while conducting research on an object. (ANTARA/HO-Humas Universitas Brawijaya)"The newly identified microalgae genera are Paracatenula and Wallaceago," head of the research team and lecturer at UB’s Faculty of Fisheries and Marine Sciences, Oktiyas Muzaky Luthfi stated in Malang, East Java, on Friday.The genus name Wallaceago was chosen to honor Alfred Russel Wallace -- a renowned naturalist, explorer, geographer, anthropologist, and expert on species distribution.Each of the two new genera also includes newly identified species: Paracatenula porostriata and Wallaceago porostriatus.Discovered near Bawean Island, Paracatenula porostriata is characterized by a circular shell structure with small pores and a flat valve.Meanwhile, Wallaceago porostriatus, found in Tomini Bay, has valves that are partially diamond-shaped with fine lines on the lower surface.These discoveries have already been published in an international scientific journal.In addition to Paracatenula and Wallaceago, the UB team also identified several new species within the genera Catenula and Catenulopsis.According to a summary of the published journal, four new species were found in the genus Catenula: Catenula boyanensis, Catenula komodensis, Catenula decusa, and Catenula densestriata.These species were discovered in Bawean Island, Tiga Warna Beach in Malang, East Java, and Tomini Bay, Central Sulawesi.One more species identified under the genus Catenulopsis was named Catenulopsis baweana."We discovered it in Bawean, which is why it is named baweana," Luthfi explained.The research and identification process took place from 2021 to 2024, using both light microscopy and scanning electron microscopy (SEM) for morphological analysis.Researchers explored the diversity of diatoms from sediment and fragments of dead coral in reef environments.The study involved collaboration with several universities from different countries, including the University of Szczecin and the University of Rzeszów in Poland, as well as the University of Michigan in the United States.Luthfi emphasized that the discovery is important for sustaining life on Earth, as microalgae not only form the foundation of the food chain but also play a vital role in oxygen production."Microalgae are responsible for generating 20 percent of the Earth’s oxygen," he noted.He remarked that this discovery provides a foundation for monitoring marine environments, studying tropical aquatic ecology, and conducting paleoecological research."This proves that Indonesia’s oceans harbor an abundance of microscopic life that we have yet to fully understand," he concluded.For more information please click: https://ub.ac.idBrawijaya University: https://prasetya.ub.ac.idEditor : A Malik Ibrahim, Copyright (c) ANTARA 2025 Copyright 2025 ACN Newswire via SeaPRwire.com.

Shanghai, Jun 23, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine ("the Company", stock code: 2552.HK) announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA). A preclinical animal study showed that the combination of dorzagliatin and sitagliptin, a DPP-4 inhibitor, improves blood glucose levels, promotes insulin secretion, and enhances GLP-1 secretion. The combination therapy was more effective than dorzagliatin alone. The blood chemistry analysis further indicates that the combination therapy has potential benefits for lipid lowering (especially LDL) (See Figure 1).Dorzagliatin is the world's first glucokinase activator independently developed by Hua Medicine, aiming to restore the imbalanced blood glucose levels in patients with type 2 diabetes by repairing the impaired function and expression of glucokinase and enhancing glucose sensitivity in patients with type 2 diabetes. Sitagliptin, a DPP4 inhibitor, improves glucose control by blocking degradation of GLP-1. This study aims to assess the impact of long-term administration of dorzagliatin and the combination of dorzagliatin/sitagliptin on glucose homeostasis in high-fat diet-induced obesity/diabetes (DIO) mice.In the study, the DIO mice were administered dorzagliatin at a dosage of 30 mg/Kg/day, or a combination of dorzagliatin (same dose) and sitagliptin (20mg/Kg/day) for 30 days. Mice on a standard diet served as controls. On day 30, the glucose levels were all reduced compared to pre-treatment, and the combination therapy was more effective than dorzagliatin alone. Dorzagliatin monotherapy promoted insulin and GLP-1 secretion, and the combination resulted in a further increase.Blood biochemical analysis showed that drug treatment significantly improved glycated serum protein (GSP) in DIO mice. Combination therapy also improved low-density lipoprotein (LDL) levels. LDL transports cholesterol to arteries, and excessive LDL can cause arteriosclerosis, myocardial infarction, stroke, and peripheral arterial diseases. These results suggest that combination therapy has potential benefits reducing blood lipids (especially LDL) while restoring glucose homeostasis, exploring possibilities for clinical medication and new indication expansion. Figure 1 Blood Biochemical 2025 ADA 893-PAnother investigator-initiated real-world study was also presented at the ADA conference. This single-center prospective observational study aimed to evaluate the short-term efficacy and underlying mechanisms of dorzagliatin in T2DM patients. Interim analysis showed significant reductions in HbA1c levels, improvements in continuous glucose monitoring parameters, and protection of β-cell insulin secretion capacity as indicated by β-cell function indices (See Figure 2). The key analysis data are as follows:HbA1c- decreased significantly from 8.1±1.2% at baseline to 7.3±1.1% at 3 months- sustained the reduction to 7.3±1.1% at 6 months (both p<0.0001).CGM metrics- TIR increased from 65.8±22.1% to 70.3±21.5% (p=0.047) at 6 months- TAR decreased from 31.8±22.7% to 25.7±21.6% (p=0.033).β-cell function index AUC_CP- improved by 10.9% at 6 months (p<0.0001)(Figure 2 improvements of glycated hemoglobin, CGM metrics, β-cell function from baseline to 6 months 2025ADA 2004-LB)These real-world clinical application cases confirm that dorzagliatin, as a GKA, can improve glucose sensitivity, regulate blood glucose levels, and improves glycemic homeostasis and β-cell function in T2DM patients, supporting GKAs' unique therapeutic position in diabetes management, distinct from conventional hypoglycemic agents. Researchers will continue to evaluate the long-term efficacy of dorzagliatin and the long-term effects of pancreatic function preservation through follow-up.Additionally, Hua Medicine was again invited to the official ADA TV channel during the ADA conference to present a series of films discussing the global diabetes management landscape and the clinical application value of dorzagliatin in various fields.Hua Medicine will continue to conduct preclinical and clinical research, and through extensive cooperation with clinicians, further explore the clinical application potential of dorzagliatin to expand the Company's future product pipeline and disease areas.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsWebsite: ir@huamedicine.comMediaWebsite: pr@huamedicine.com Copyright 2025 ACN Newswire via SeaPRwire.com.

上海 ，2025年6月23日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552.HK）今天宣布，第85届美国糖尿病协会（ADA）科学年会上，公司展示了其全球首创新药葡萄糖激酶激活剂（GKA）多格列艾汀（dorzagliatin）的最新研究成果。一项基础动物研究表明，多格列艾汀联合DPP-4抑制剂西格列汀（Sitagliptin）使用可以改善血糖水平、促进胰岛素分泌、增强GLP-1分泌等，效果优于多格列艾汀单独用药。血液生化分析则显示，联合用药对于降低血脂（特别是LDL）有潜在获益（见图1）。多格列艾汀是华领医药自主研发的全球首创葡萄糖激酶激活剂，通过修复2型糖尿病患者受损的葡萄糖激酶（GK）功能和表达，提升2型糖尿病患者的葡萄糖敏感性，从而改善患者血糖稳态失调。西格列汀（Sitagliptin）是一款DPP-4抑制剂类降糖药，通过抑制GLP-1降解改善血糖控制。该研究旨在评估两药联用长期治疗对高脂饮食诱导肥胖/糖尿病(DIO)小鼠葡萄糖稳态的影响，为临床联合用药提供依据。研究对于DIO小鼠模型分别给予30 mg/kg/天的多格列艾汀单药或联合20 mg/kg/天的西格列汀治疗30天，以标准饮食小鼠作为对照。治疗30天后，小鼠血糖水平较治疗前显著改善，且联合用药治疗效果优于单独用药。多格列艾汀单独用药可促进胰岛素和GLP-1的分泌，联合用药进一步增强了这一效应。血液生化指标分析则显示，药物治疗显著改善了DIO小鼠的糖化血清蛋白（GSP），联合治疗还改善了低密度脂蛋白（LDL）水平。低密度脂蛋白将胆固醇运送至动脉，过量的低密度脂蛋白会造成动脉硬化、心肌梗塞、中风及周围动脉疾病等。这一结果表明，联合用药在恢复血糖稳态的同时，对于降低血脂（特别是LDL）有潜在获益，为临床用药和新适应症的拓展探索了可能性。（图1 血液生化指标 2025 ADA 893-P）另一项研究者发起的真实世界研究也在ADA年会上进行了展示。该研究是一项单中心前瞻性观察性研究，旨在评估多格列艾汀在2型糖尿病患者中的短期疗效及机制。中期分析显示，患者的糖化血红蛋白（HbA1c）水平显著降低，连续血糖监测（CGM）指标改善，β细胞功能指标分析提示β细胞的胰岛素分泌功能得到保护(见图2)。重点分析数据如下：HbA1c：- 治疗3个月后，从基线水平8.1±1.2%显著降至7.3±1.1%，6个月时维持该水平（均p<0.0001），提示血糖长期控制效果显著CGM指标：- 目标范围内时间（TIR, Time in Range）：6个月时，从65.8±22.1%升至70.3±21.5（p=0.047），表明血糖在目标区间（通常3.9-10.0 mmol/L）的时间占比增加- 高于目标范围时间（TAR, Time above Range）:≥10.0 mmol/L从31.8±22.7%降至25.7±21.6%（p=0.033），提示高血糖持续时间缩短β细胞功能指标（AUC_CP）：- 6个月时，改善了10.9% (p<0.0001) （图2 从基线到6个月时糖化血红蛋白、持续葡萄糖监测指标及β细胞功能的改善2025ADA 2004-LB）这些真实世界的临床应用案例证实了多格列艾汀作为GKA可以直接改善葡萄糖敏感性，改善2型糖尿病患者的血糖水平，恢复患者的血糖稳态和显著改善β细胞功能，支持了GKA在糖尿病管理中不同于传统降糖药的独特治疗地位。研究者还将通过随访继续评估多格列艾汀的长期疗效，评估胰岛功能保护的长期效应。此外，华领医药再次受邀于ADA年会期间，在官方电视频道ADA TV报道系列影片，讲述全球糖尿病管理格局，以及多格列艾汀在不同领域的临床应用价值。华领医药将继续开展基础研究和临床研究，同时通过与临床医生的广泛合作，进一步探索多格列艾汀的临床应用潜力，拓展公司未来产品管线和疾病领域。关于华领华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁®（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁®已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com Copyright 2025 亚太商讯 via SeaPRwire.com.